Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents
Authors:
- Clare MurrayCMClare Murray
- Eva GalvanEva Galvan
- Carlos OntiverosCOCarlos Ontiveros
- Yilun DengYDYilun Deng
- Haiyan BaiHBHaiyan Bai
- Alvaro Souto PadronAPAlvaro Souto Padron
- Kathryn Hinchee-RodriguezKHKathryn Hinchee-Rodriguez
- Myrna G. GarciaMGMyrna G. Garcia
- Anand KornepatiAKAnand Kornepati
- Jose Conejo-GarciaJCJose Conejo-Garcia
- Tyler J. CurielTCTyler J. Curiel
Open Access
- 4 May 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (9) , 5129
Abstract
The interaction between tumor surface-expressed PDL1 and immune cell PD1 for the evasion of antitumor immunity is well established and is targeted by FDA-approved anti-PDL1 and anti-PD1 antibodies. Nonetheless, recent studies highlight the immunopathogenicity of tumor-intrinsic PDL1 signals that can contribute to the resistance to targeted small molecules, cytotoxic chemotherapy, and αPD1 immunotherapy. As genetic PDL1 depletion is not currently clinically tractable, we screened FDA-approved drugs to identify those that significantly deplete tumor PDL1. Among the candidates, we identified the β-lactam cephalosporin antibiotic cefepime as a tumor PDL1-depleting drug (PDD) that increases tumor DNA damage and sensitivity to DNA-damaging agents in vitro in distinct aggressive mouse and human cancer lines, including glioblastoma multiforme, ovarian cancer, bladder cancer, and melanoma. Cefepime reduced tumor PDL1 post-translationally through ubiquitination, improved DNA-damaging-agent treatment efficacy in vivo in immune-deficient and -proficient mice, activated immunogenic tumor STING signals, and phenocopied specific genetic PDL1 depletion effects. The β-lactam ring and its antibiotic properties did not appear contributory to PDL1 depletion or to these treatment effects, and the related cephalosporin ceftazidime produced similar effects. Our findings highlight the rapidly translated potential for PDDs to inhibit tumor-intrinsic PDL1 signals and improve DNA-damaging agents and immunotherapy efficacy.Keywords
Funding Information
- NIH T32GM113896 (STX MSTP) Award (T32GM113896, TL1 TR002647, CA204965, CA054515)
- National Center for Advancing Translational Sciences, National Institutes of Health (T32GM113896, TL1 TR002647, CA204965, CA054515)
- Clayton Foundation (T32GM113896, TL1 TR002647, CA204965, CA054515)
- NCI (T32GM113896, TL1 TR002647, CA204965, CA054515)
This publication has 38 references indexed in Scilit:
- Deubiquitination and Stabilization of PD-L1 by CSN5Cancer Cell, 2016
- Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveCancer Chemotherapy and Pharmacology, 2016
- Bactericidal Antibiotics Induce Mitochondrial Dysfunction and Oxidative Damage in Mammalian CellsScience Translational Medicine, 2013
- Calreticulin exposure dictates the immunogenicity of cancer cell deathNature Medicine, 2006
- Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in gliomaNature Medicine, 2006
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- CefepimeAmerican Journal of Respiratory Medicine, 2003
- Temozolomide, a Novel Alkylating Agent with Activity in the Central Nervous System, May Improve the Treatment of Advanced Metastatic MelanomaThe Oncologist, 2000
- Flexible Programs of Chemokine Receptor Expression on Human Polarized T Helper 1 and 2 LymphocytesJournal of Experimental Medicine, 1998